(Total Views: 213)
Posted On: 11/20/2019 11:09:58 AM
Post# of 36566
So much for an updated website. How about updating the content...
Under the Family of Companies tab, then down in NGIO section...
"The FDA has accepted an IND for a Phase II clinical trial evaluating AE37, our Ii-Key immunotherapeutic vaccine, in combination with pembrolizumab for the treatment of triple negative breast cancer. The trial is being conducted with research partners, Merck and the NSABP (National Surgical Adjuvant Breast and Bowel Project). The NSABP clinical research sites are currently being initiated and patient enrollment will begin in the first quarter of 2019."
Since we are in the 4th quarter of 2019, maybe say "began" instead of "will begin"?
Under the Family of Companies tab, then down in NGIO section...
"The FDA has accepted an IND for a Phase II clinical trial evaluating AE37, our Ii-Key immunotherapeutic vaccine, in combination with pembrolizumab for the treatment of triple negative breast cancer. The trial is being conducted with research partners, Merck and the NSABP (National Surgical Adjuvant Breast and Bowel Project). The NSABP clinical research sites are currently being initiated and patient enrollment will begin in the first quarter of 2019."
Since we are in the 4th quarter of 2019, maybe say "began" instead of "will begin"?
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
